Health statistics: time to get serious

by Kenji Shibuya, Suzanne Scheele, Ties Boerma
Published 2005-10-01

What Drives the Value of a <i>Shigella</i> Vaccine?

by William P. Hausdorff, Suzanne Scheele, Birgitte K. Giersing
Published 2022-02-01

Shigella and childhood stunting: Evidence, gaps, and future research directions.

by Karoun H Bagamian, John D Anderson Iv, Gabriela Blohm, Suzanne Scheele
Published 2023-09-01

New methods for estimating the tuberculosis case detection rate in high-HIV prevalence countries: the example of Kenya

by John Mansoer, Suzanne Scheele, Katherine Floyd, Christopher Dye, Joseph Sitienei, Brian Williams
Published 2009-03-01

Could a Shigella vaccine impact long-term health outcomes?: Summary report of an expert meeting to inform a Shigella vaccine public health value proposition, March 24 and 29, 2021

by Karoun H. Bagamian, Chloe Puett, John D. Anderson, IV, Farzana Muhib, Clint Pecenka, Jere Behrman, Robert F. Breiman, Ijeoma Edoka, Susan Horton, Gagandeep Kang, Karen L. Kotloff, Claudio F. Lanata, James A. Platts-Mills, Firdausi Qadri, Elizabeth T. Rogawski McQuade, Christopher Sudfeld, Pascale Vonaesch, Thomas F. Wierzba, Suzanne Scheele
Published 2022-12-01